Imperial College London

Professor Martin Wilkins

Faculty of MedicineDepartment of Medicine

Head of the Department of Medicine
 
 
 
//

Contact

 

+44 (0)20 3313 2049m.wilkins

 
 
//

Location

 

NIHR / Wellcome Trust Clinical Research FacilityICTEM buildingHammersmith Campus

//

Summary

 

Summary

Martin R. Wilkins is Professor of Clinical Pharmacology at Imperial College London. He is Head of the Department of Medicine, a role he combines with Director of the National Institute of Health Research /  Wellcome Trust Imperial Clinical Research Facility, which is based at Hammersmith Hospital, and the Wellcome Trust Translational Medicine Training Programme.

He played a major role in shaping the Imperial Academic Health Sciences Centre through his joint academic role and leadership of a large clinical programme group within the NHS Trust. He has dedicated substantial time to aligning the academic mission of the College and the clinical service in the Trust to provide an environment that places Imperial College at the forefront of Translational Medicine.

His primary research interest is in proof-of-concept studies in humans.  He uses pulmonary hypertension as a paradigm for developing novel therapies from the laboratory to patients. 

Selected Publications

Journal Articles

Zhao L, Oliver E, Maratou K, et al., 2015, The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia, Nature, Vol:524, ISSN:0028-0836, Pages:356-U229

Wilkins MR, Ghofrani H-A, Weissmann N, et al., 2015, Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease, Circulation, Vol:131, ISSN:0009-7322, Pages:582-590

Wilkins MR, Aldashev AA, Wharton J, et al., 2014, alpha 1-A680T Variant in GUCY1A3 as a Candidate Conferring Protection From Pulmonary Hypertension Among Kyrgyz Highlanders, Circulation-Cardiovascular Genetics, Vol:7, ISSN:1942-325X, Pages:920-U505

Wojciak-Stothard B, Abdul-Salam VB, Lao KH, et al., 2014, Aberrant Chloride Intracellular Channel 4 Expression Contributes to Endothelial Dysfunction in Pulmonary Arterial Hypertension, Circulation, Vol:129, ISSN:0009-7322, Pages:1770-1780

Ghofrani HA, D'Armini AM, Grimminger F, et al., 2013, Riociguat for the treatment of chronic thromboembolic pulmonary hypertension., N Engl J Med, Vol:369, Pages:319-329

Zhao L, Ashek A, Wang L, et al., 2013, Heterogeneity in Lung (18)FDG Uptake in Pulmonary Arterial Hypertension Potential of Dynamic (18)FDG Positron Emission Tomography With Kinetic Analysis as a Bridging Biomarker for Pulmonary Vascular Remodeling Targeted Treatments, Circulation, Vol:128, ISSN:0009-7322, Pages:1214-1224

Rhodes CJ, Wharton J, Boon RA, et al., 2013, Reduced MicroRNA-150 Is Associated with Poor Survival in Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, Vol:187, ISSN:1073-449X, Pages:294-302

Zhao L, Chen C-N, Hajji N, et al., 2012, Histone Deacetylation Inhibition in Pulmonary Hypertension Therapeutic Potential of Valproic Acid and Suberoylanilide Hydroxamic Acid, Circulation, Vol:126, ISSN:0009-7322, Pages:455-+

Wojciak-Stothard B, Zhao L, Oliver E, et al., 2012, Role of RhoB in the Regulation of Pulmonary Endothelial and Smooth Muscle Cell Responses to Hypoxia, Circulation Research, Vol:110, ISSN:0009-7330, Pages:1423-+

Schermuly RT, Ghofrani HA, Wilkins MR, et al., 2011, Mechanisms of disease: pulmonary arterial hypertension, Nature Reviews Cardiology, Vol:8, ISSN:1759-5002, Pages:443-455

Rhodes CJ, Howard LS, Busbridge M, et al., 2011, Iron Deficiency and Raised Hepcidin in Idiopathic Pulmonary Arterial Hypertension Clinical Prevalence, Outcomes, and Mechanistic Insights, Journal of the American College of Cardiology, Vol:58, ISSN:0735-1097, Pages:300-309

Rhodes CJ, Wharton J, Howard LS, et al., 2011, Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension, Heart, Vol:97, ISSN:1355-6037, Pages:1054-1060

Rhodes CJ, Wharton J, Howard L, et al., 2011, Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target, European Respiratory Journal, Vol:38, ISSN:0903-1936, Pages:1453-1460

Abdul-Salam VB, Wharton J, Cupitt J, et al., 2010, Proteomic Analysis of Lung Tissues From Patients With Pulmonary Arterial Hypertension, Circulation, Vol:122, ISSN:0009-7322, Pages:2058-U282

Archer SL, Weir EK, Wilkins MR, 2010, Basic Science of Pulmonary Arterial Hypertension for Clinicians New Concepts and Experimental Therapies, Circulation, Vol:121, ISSN:0009-7322, Pages:2045-U175

Wilkins MR, Ali O, Bradlow W, et al., 2010, Simvastatin as a Treatment for Pulmonary Hypertension Trial, American Journal of Respiratory and Critical Care Medicine, Vol:181, ISSN:1073-449X, Pages:1106-1113

Michelakis ED, Wilkins MR, Rabinovitch M, 2008, Emerging concepts and translational priorities in pulmonary arterial hypertension, Circulation, Vol:118, ISSN:0009-7322, Pages:1486-1495

Nickel N, Kempf T, Tapken H, et al., 2008, Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension, American Journal of Respiratory and Critical Care Medicine, Vol:178, ISSN:1073-449X, Pages:534-541

Wilkins MR, Wharton J, Grimminger F, et al., 2008, Phosphodiesterase inhibitors for the treatment of pulmonary hypertension, European Respiratory Journal, Vol:32, ISSN:0903-1936, Pages:198-209

Aldashev AA, Kojonazarov BK, Amatov TA, et al., 2005, Phosphodiesterase type 5 and high altitude pulmonary hypertension, Thorax, Vol:60, ISSN:0040-6376, Pages:683-687

Wharton J, Strange JW, Moller GMO, et al., 2005, Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells, American Journal of Respiratory and Critical Care Medicine, Vol:172, ISSN:1073-449X, Pages:105-113

Paul GA, Gibbs JSR, Boobis AR, et al., 2005, Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension, British Journal of Clinical Pharmacology, Vol:60, ISSN:0306-5251, Pages:107-112

Wilkins MR, Paul GA, Strange JW, et al., 2005, Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study, American Journal of Respiratory and Critical Care Medicine, Vol:171, ISSN:1073-449X, Pages:1292-1297

Khoo JP, Zhao L, Alp NJ, et al., 2005, Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension, Circulation, Vol:111, ISSN:0009-7322, Pages:2126-2133

More Publications